BioLingus
Hergiswil, Nidwalden, Switzerland
About BioLingus
Biolingus is a Swiss biotech company spearheading the development of oral (sublingual) and mucosal delivery of peptides and proteins. Our technology is derived from applied bio-engineering, resulting in novel bio-mimetic materials. It is a cutting-edge and mature solution for oral formulations not only for peptides but also proteins, novel protein scaffolds, vaccines, immunotherapies, enzymes and also very hydrophobic small molecules. The company focuses the development of its own products on treatment of chronic diseases, such as diabetes and inflammatory diseases. In addition to that, a particular area of interest is oral immunotherapy, as our technology has shown an outstanding performance in this area. BioLingus’ main office is in Switzerland, and we have a satellite company in Hong Kong.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Last round: Grant (Sep 2022)
- Website: biolingus.ch
- Phone: [email protected]
Industries & Categories
Biometrics, Biotechnology, Health Care, Medical Device, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/biolingus-2556138 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.